Our results regarding the adverse prognostic effect of EGFR in the entire group of intestinal-type, but not in pancreatobiliary type, adenocarcinoma confirm the results of Xia et al [15], and further underscore the biological differences between pancreatobiliary and intestinal type periampullary adenocarcinomas. Here, EGFR is linked to adenocarcinoma.